Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching pulmonary fibrosis may encounter menstrual-blood-derived mesenchymal stem cell (MSC) therapy as an emerging treatment option. In China, this therapy is currently available through the Boao Lecheng supervised pilot pathway in Hainan as part of the third batch of approved projects. This guide explains what the treatment is, who may be considered, its estimated cost, where it is offered, and what international patients should know before pursuing it.
Image alt text: Menstrual-blood-derived mesenchymal stem cell therapy for pulmonary fibrosis in China at Shu Lan (Boao) Hospital.
Image caption: Menstrual-blood-derived MSC therapy for pulmonary fibrosis is available through the Boao Lecheng pilot pathway at Shu Lan (Boao) Hospital in Hainan.
Key Takeaways |
|
What Is Pulmonary Fibrosis Stem Cell Therapy China?
Menstrual-Blood MSC Therapy uses mesenchymal stem cells derived from uterine blood. The treatment is designed as a cell-based therapy for patients with pulmonary fibrosis, with the course consisting of three injections.
The cell source is distinct from other MSC products that may use bone marrow, adipose tissue, umbilical cord tissue, or other sources. Here, the cells are derived from uterine blood and are processed for therapeutic use.
Clinical evidence for cell-based approaches to pulmonary fibrosis remains under evaluation. Availability through a supervised medical-access pathway should not be interpreted as proof that the therapy cures pulmonary fibrosis or is superior to established treatment.
Is Pulmonary Fibrosis Stem Cell Therapy China Available?
Yes. Menstrual-blood MSC therapy for pulmonary fibrosis is available through the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. The project is part of the third batch of approved Boao Lecheng projects, with a registration date of 2025 and a low-risk classification.
This pathway is different from nationwide approval for routine use across China. Patients therefore need to access the therapy through the designated hospital and undergo medical assessment before treatment can proceed.
For international patients, this means the relevant question is not simply whether stem cell therapy exists in China, but whether this specific therapy and hospital can currently accept the patient's case through the Lecheng pathway.
Where Is the Treatment Offered?
The treatment is offered at Shu Lan (Boao) Hospital in Hainan.
Technical support is provided by Zhejiang Shengchuang Precision Medical Technology Co., Ltd. The cell source is uterine blood-derived mesenchymal stem cells.
Patients should confirm current treatment availability, appointment procedures, medical documentation requirements, and travel arrangements directly with the hospital before making plans.
Who May Be Eligible?
Eligibility criteria are PF-ILD patients showing continued progressive fibrosis despite standard treatment. Suitability is assessed face-to-face by the attending physician.
The eligibility criterion does not by itself determine whether an individual patient qualifies. Medical records, disease history, previous treatment, and the patient's current clinical status may need to be reviewed by the treating team.
Final eligibility is determined by the treating medical team after a face-to-face consultation or review of the patient's medical records.
How Much Does It Cost?
The estimated cost is ¥140,000 (approximately US$20,800) per course of three injections. The USD figure uses a reference exchange rate of about 6.72 CNY per US dollar as of August 28, 2026.
The stated treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or travel expenses. Confirm final pricing and the full scope of the course directly with the hospital before treatment.
Why International Patients May Consider This Option
For some international patients with progressive pulmonary fibrosis despite standard treatment, a supervised access pathway for an MSC-based therapy may be an option to discuss with a qualified specialist.
The Boao Lecheng pathway provides a specific hospital-based route for exploring this treatment in China.
However, pilot-zone access does not establish nationwide approval, and treatment availability does not guarantee an individual patient's eligibility or a particular clinical outcome.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and pulmonary fibrosis-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Shu Lan (Boao) Hospital in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This Treatment in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is pulmonary fibrosis stem cell therapy China available to international patients?
Yes. Menstrual-blood MSC therapy for pulmonary fibrosis is available through the Boao Lecheng pilot pathway at Shu Lan (Boao) Hospital, subject to medical assessment and current hospital availability.
How much does pulmonary fibrosis stem cell therapy cost in China?
The estimated cost is ¥140,000, or approximately US$20,800, for a course of three injections. Patients should confirm final pricing and inclusions directly with the hospital.
Who may qualify for menstrual-blood MSC therapy for pulmonary fibrosis?
Patients with PF-ILD showing continued progressive fibrosis despite standard treatment may be considered. Final eligibility is determined by the treating medical team after medical review and face-to-face assessment.
Is this pulmonary fibrosis stem cell therapy approved throughout China?
No. The therapy is included in the third batch of approved Boao Lecheng projects in Hainan. This pilot-zone access status does not mean nationwide approval for routine use throughout China.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
